Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for MDD in Type 2 Diabetes
NCT03580967Phase 4Withdrawn
- Sponsor
- Todd Doyle
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vortioxetine in major depressive disorder (MDD), sponsored by Todd Doyle. Planned start Jul 2019; status: withdrawn.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03580967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580967.